|
TOP
|
|
APTIVUS®(二十四)
|
.31, 1.43) |
|
Efavirenz |
600 mg QD
(8 doses) |
500/100 mg BID* |
21 (89) |
↓ |
0.79 (0.69, 0.89) |
0.69 (0.57, 0.83) |
0.58 (0.36, 0.86) |
|
|
|
750/200 mg BID* |
25 (100) |
↔ |
0.97 (0.85, 1.09) |
1.01 (0.85, 1.18) |
0.97 (0.69, 1.28) |
Ethinyl estradiol
/Norethindrone |
0.035/1.0 mg
(1 dose) |
500/100 mg BID
(21 doses) |
21 |
↓ |
1.10 (0.98, 1.24) |
0.98 (0.88, 1.11) |
0.73 (0.59, 0.90) |
|
|
|
750/200 mg BID
(21 doses) |
13 |
↔ |
1.01 (0.96, 1.06) |
0.98 (0.90, 1.07) |
0.91 (0.69, 1.20) |
|
Fluconazole |
100 mg QD
(12 doses) |
500/200 mg BID* |
20 (68) |
↑ |
1.32 (1.18, 1.47) |
1.50 (1.29, 1.73) |
1.69 (1.33, 2.09) |
|
Loperamide |
16 mg
(1 dose) |
750/200 mg BID
(21 doses) |
24 |
↓ |
1.03 (0.92, 1.17) |
0.98 (0.86, 1.12) |
0.74 (0.62, 0.88) |
|
Rifabutin |
150 mg
(1 dose) |
500/200 mg BID
(15 doses) |
21 |
↔ |
0.99 (0.93, 1.07) |
1.00 (0.96, 1.04) |
1.16 (1.07, 1.27) |
|
Rosuvastatin |
10 mg
(1 dose) |
500/200 mg BID
(24 doses) |
16 |
↔ |
1.08 (1.00, 1.17) |
1.06 (0.97, 1.15) |
0.99 (0.88, 1.11) |
|
Tadalafil |
10 mg
(1 dose) |
500/200 mg BID
(17 doses) |
17 |
↔ |
0.90 (0.80, 1.01) |
0.85 (0.74, 0.97) |
0.81 (0.70, 0.94) |
|
Tenofovir |
300 mg
(1 dose) |
500/100 mg BID |
22 |
↓ |
0.83 (0.74, 0.94) |
0.82 (0.75, 0.91) |
0.79 (0.70, 0.90) |
|
|
|
750/200 mg BID
(23 doses) |
20 |
↔ |
0.89 (0.84, 0.96) |
0.91 (0.85, 0.97) |
0.88 (0.78, 1.00) |
|
Zidovudine |
300 mg
(1 dose) |
500/100 mg BID |
29 |
↓ |
0.87 (0.80, 0.94) |
0.82 (0.76, 0.89) |
0.77 (0.68, 0.87) |
|
|
|
750/200 mg BID
(23 doses) |
25 |
↔ |
1.02 (0.94, 1.10) |
1.02 (0.92, 1.13) |
1.07 (0.86, 1.34) |
Table 8 Drug Interactions: Pharmacokinetic Parameters for Co-administered Drug in the Presence of APTIVUS/ritonavir
|
Co-administered Drug |
Co-administered Drug Dose (Schedule) |
tipranavir/ritonavir Drug Dose (Schedule) |
n |
PK |
Ratio (90% Confidence Interval) of Co-administered Drug
Pharmacokinetic Parameters with/without
tipra
|
|
